Bristol-Myers Is Confronting Overhead Resistance and a Lack of Aggressive Buying

Let's take a fresh look at the charts.

PetIQ Has Broken Out on the Upside - Time to Go Long

Let's check the charts and indicators.

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

The answer is plenty, but you can't trade that.

Allergan Has Finally Made a Base Pattern Traders Can Approach From the Long Side

Let's check out the charts again so see how far this advance might carry.

J&J Stock Is Firming Up Nicely, Stay Long

Let's check some updated charts to see if our strategy is still on track.

Merck Shares Slip Despite 'Milestone' Lung Cancer Drug Approval

Merck shares retreat as regulatory approval ramps up speculation.

Jim Cramer: This Is a Rotation, Not a Recession

There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.

Jim Cramer: The Great Ones Disrupt Their Own

Two companies, PepsiCo and Constellation Brands, are disrupting their own businesses and getting no credit whatsoever for doing so.

MedMen sees traction in California despite market challenges

Matt Karnes, the founder of cannabis industry analytics firm GreenWave Advisors, said that based on his estimates of public sales and dispensary data, MedMen is outpacing the statewide average between $200,000 and $250,000 quarterly revenue per store.

Aetna Reached Our Target Price and Is Still Bullish

A fresh look is certainly warranted and perhaps overdue.